Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Energy Vault Q4 2025 Earnings Call - Asset Vault shift drives 540 MW contracted and Q4 positive adjusted EBITDA
Energy Vault closed 2025 with a sharp operational pivot paying off. Q4 revenue surged to $153.3 million and full-year revenue reached $203.7 million, helping the company record positive adjusted EBITD...
- Q4 2025 revenue was $153.3 million; full-year 2025 revenue was $203.7 million, up over 340% year-over-year.
- Q4 GAAP gross profit was $31.6 million and full-year GAAP gross profit was $48 million, an nearly 8x improvement versus prior year.
- Full-year gross margin expanded to 23.6% in 2025 from 13.4% in 2024, driven by scale and favorable business mix.
- +13 more takeaways
Cibus Q4 2025 Earnings Call - Rice royalties and regulatory wins set up 2027 launches, runway tight into late Q3 2026
Cibus says 2025 was a turning point, citing technical gains, regulatory progress and initial commercial receipts that collectively position the company to begin royalty generation from gene-edited ric...
- Cibus calls 2025 a landmark year, driven by converging technology, commercialization, scale, and regulatory momentum.
- Seven rice customers represent a stated potential annual royalty opportunity of over $200 million, focused initially on herbicide-tolerant traits.
- Management expects initial commercial entry for rice in Latin America in 2027, U.S. expansion in 2028, and India/Asia closer to 2030.
- +12 more takeaways
ClearPoint Neuro, Inc. Q4 & Full Year 2025 Earnings Call - Tightened 2026 Guidance as FDA Rare-Disease Signals and IRRAS Integration Shift Near-Term Upside
ClearPoint closed 2025 with momentum and a newly acquired IRRAS product line, but management tightened 2026 guidance to $52 million-$56 million after factoring in recent FDA communications on rare-dis...
- 2026 guidance set to $52.0M to $56.0M, tightened to reflect recent FDA communications on rare-disease trial rigor and IRRAS integration priorities, with any positive FDA developments treated as upside.
- Full year 2025 revenue was $37.0 million, up from $31.4 million in 2024; fourth quarter revenue was $10.4 million versus $7.8 million in Q4 2024.
- Biologics and Drug Delivery revenue rose 10% to $19.0M for 2025, and increased 23% in Q4 to $5.2M, driven by higher disposable product demand from advancing partner trials.
- +12 more takeaways
Trevi Therapeutics Q4 2025 Earnings Call - FDA Aligns on Two Phase 3 Trials and Clear NDA Path for IPF-Related Chronic Cough
Trevi heads into 2026 with momentum. After positive 2025 CORAL and RIVER data, the company held a constructive end-of-phase 2 meeting with the FDA that produced a defined path to an NDA for IPF-relate...
- Trevi had two positive 2025 readouts, CORAL (IPF chronic cough) and RIVER (refractory chronic cough), that underpin the current acceleration of clinical programs.
- Following a collaborative end-of-phase 2 meeting, the FDA and Trevi agreed the primary endpoint for IPF-related chronic cough will be objective cough monitoring, and the development path toward an NDA is clear.
- Trevi will run two parallel pivotal phase 3 trials in IPF-related chronic cough: a global 52-week trial (primary efficacy at 24 weeks, ~300 patients) starting in Q2, and a confirmatory global trial (primary efficacy at 12 weeks, ~130 patients) starting in H2.
- +11 more takeaways
NextNav Q4 2025 Earnings Call - FCC Draft NPRM Sent to OMB, Company Sees Direct Path to Report and Order
NextNav used its Q4 call to put the FCC process front and center. Management confirmed a draft notice of proposed rulemaking on positioning, navigation, and timing technologies has been sent to the Wh...
- FCC process update: FCC has formally sent a draft NPRM on PNT technologies to the White House OMB, and NextNav says it expects the NPRM to progress to a Report and Order, though timing is out of the company’s control.
- NextNav claims a unique role: management says NextNav provides a one-of-one combination of wide-scale positioning, timing, and 3D geolocation that fits into a system-of-systems approach to back up GPS.
- Experimental 5G PNT testing: NextNav is operating an experimental license for what it calls the world’s first 5G-powered PNT network in a defined geographic area; company stresses this testing is for early commercialization and separate from the FCC NPRM process.
- +12 more takeaways
Comscore Q4 2025 Earnings Call - CCM and recapitalization free up cash to push cross-platform growth
Comscore closed 2025 with modest top-line progress and clearer strategic direction. Full-year revenue was $357.5 million, up 0.4% year-over-year, while adjusted EBITDA rose 2.6% to $42 million, reflec...
- Full-year 2025 revenue was $357.5 million, up 0.4% versus 2024, and adjusted EBITDA rose to $42 million, a 2.6% increase, driving an 11.8% adjusted EBITDA margin for the year.
- Cross-platform revenue was $50.3 million in 2025, growing 24.4% year-over-year, making it the fastest-growing segment and the companys primary growth lever going into 2026.
- Comscore launched CCM, its cross-platform content measurement product, which management says achieved early adoption from several large broadcasters and technology companies, and will receive further feature rollouts in 2026.
- +11 more takeaways
Longeveron FY2025 Earnings Call - Pivotal HLHS Readout Expected Q3 2026, Runway Into Q4 2026
Longeveron is selling a near-term narrative built around a single binary event. The company closed a $15.9 million private placement with Coastlands Capital and Janus Henderson that, together with exi...
- Company raised ~$15.9 million in a March 2026 private placement with Coastlands Capital and Janus Henderson, providing runway into Q4 2026 per management.
- There is a potential second tranche of approximately $15 million tied to future milestones, not guaranteed, and timing/conditions were not detailed on the call.
- ELPIS-II (HLHS) enrollment of 40 patients completed in June 2025, topline results expected in Q3 2026; FDA feedback from Aug 2024 could allow ELPIS-II to serve as a pivotal study subject to the data.
- +11 more takeaways
Horizon Kinetics Fourth Quarter 2025 Earnings Call - Private investments look set to deliver a performance-fee windfall (~$22M) in Q1 2026
Horizon Kinetics reported revenue of $17.0 million in Q4 and $72.8 million for full-year 2025, with advisor-only operating income of $5.3 million for the quarter and $21.4 million for the year. The qu...
- Q4 2025 revenue was $17.0 million, full-year revenue $72.8 million, down 6.6% quarter-over-quarter and up 30.5% year-over-year respectively.
- Advisor-only operating income was $5.3 million in Q4 and $21.4 million for full-year 2025, lower than 2024 because 2024 included a $51.7 million incentive fee.
- Company reported a Q4 net loss of $0.78 per share, full-year net income of $0.28 per share; Q4 loss driven by volatility in Bitcoin-linked and other investment holdings.
- +12 more takeaways
Intelligent Protection Management Corp. Q4 2025 Earnings Call - Positive Adjusted EBITDA in Q4, but Full-Year Losses Persist
IPM closed 2025 as a transitioned managed services provider, reporting a modest but symbolic break-even at the adjusted EBITDA line in Q4 and positive operating cash flow for the year. Management tout...
- Total revenue for Q4 2025 was $6.1 million, down 1.7% sequentially; full-year 2025 revenue was $23.6 million.
- Managed IT revenue (core business) was $3.9 million in Q4 and $14.8 million for the full year; management says managed revenue excluding web hosting rose 7% sequentially in Q4.
- Procurement revenue was $1.5 million in Q4 ($5.4 million FY), professional services $0.4 million in Q4 ($2.3 million FY), and subscription revenue $0.3 million in Q4 ($1.1 million FY).
- +11 more takeaways
Consolidated Water Company Full Year 2025 Earnings Call - Hawaii Permitting Delay Defers Construction Revenue Despite Strong Cash, Record Cayman Demand
Consolidated Water closed 2025 with stable top-line, sharper dollar profits, and a liquidity cushion that gives management optionality. Retail volumes in Grand Cayman hit a record 1.09 billion gallons...
- Hawaii desal project permitting delay is the primary reason services revenue missed expectations; State Historic Preservation Division sign-off is the gating permit and the Honolulu Board of Water Supply (client) is handling the permit interactions.
- Company completed 100% design for the 1.7 MGD Kalaeloa seawater desalination plant, passed pilot testing, and secured BWS confirmation that produced water matches quality and causes no detrimental impact; construction can start once permits are issued.
- Consolidated revenue for 2025 was $132.1 million, down about 1% from 2024, with services and bulk declines offset by retail and manufacturing gains.
- +11 more takeaways